scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
scPharmaceuticals (SCPH) reported strong preliminary Q4 2024 results, with expected net revenue between $12-12.3 million, representing 99% growth over Q4 2023. The company's full-year 2024 net revenue is anticipated to reach $36.2-36.5 million, up 167% from 2023's $13.6 million.
Q4 2024 highlights include approximately 13,300 FUROSCIX doses shipped, a 23% increase from Q3's 10,800 doses. The gross-to-net discount is expected to be 18-19%, compared to 15.7% in Q3 2024. The company ended 2024 with approximately $75.7 million in cash and cash equivalents, with accounts receivable increasing 27% from September 2024.
SCPH expanded its distribution network by adding a specialty pharmacy and anticipates growth in 2025 through Medicare redesign implementation and a potential FUROSCIX indication expansion for chronic kidney disease patients in March.
scPharmaceuticals (SCPH) ha riportato risultati preliminari forti per il quarto trimestre del 2024, con ricavi netti attesi tra $12-12.3 milioni, rappresentando una crescita del 99% rispetto al quarto trimestre del 2023. Si prevede che i ricavi netti annuali per il 2024 raggiungano $36.2-36.5 milioni, in aumento del 167% rispetto ai $13.6 milioni del 2023.
I punti salienti del quarto trimestre 2024 includono circa 13.300 dosi di FUROSCIX spedite, con un incremento del 23% rispetto alle 10.800 dosi del terzo trimestre. Si stima che il sconto lordo-netto sarà del 18-19%, rispetto al 15.7% del terzo trimestre del 2024. L'azienda ha concluso il 2024 con circa $75.7 milioni in contante e equivalenti, con i crediti verso clienti aumentati del 27% da settembre 2024.
SCPH ha ampliato la propria rete distributiva aggiungendo una farmacia specializzata e prevede una crescita nel 2025 grazie all'implementazione della riforma di Medicare e a una potenziale espansione dell'indicazione di FUROSCIX per i pazienti con malattia renale cronica a marzo.
scPharmaceuticals (SCPH) reportó resultados preliminares sólidos para el cuarto trimestre de 2024, con ingresos netos esperados entre $12-12.3 millones, lo que representa un crecimiento del 99% respecto al cuarto trimestre de 2023. Se anticipa que los ingresos netos totales para el año 2024 alcanzarán $36.2-36.5 millones, un aumento del 167% con respecto a los $13.6 millones de 2023.
Los aspectos destacados del cuarto trimestre de 2024 incluyen aproximadamente 13,300 dosis de FUROSCIX enviadas, un aumento del 23% en comparación con las 10,800 dosis del tercer trimestre. Se espera que el descuento bruto-neto sea del 18-19%, en comparación con el 15.7% del tercer trimestre de 2024. La empresa cerró 2024 con aproximadamente $75.7 millones en efectivo y equivalentes, con cuentas por cobrar que aumentaron un 27% desde septiembre de 2024.
SCPH amplió su red de distribución al agregar una farmacia de especialidad y anticipa un crecimiento en 2025 mediante la implementación de la reforma de Medicare y una posible expansión de la indicación de FUROSCIX para pacientes con enfermedad renal crónica en marzo.
scPharmaceuticals (SCPH)는 2024년 4분기 강력한 예비 결과를 보고했으며, 예상 순수익은 $12-12.3 백만 사이로, 2023년 4분기 대비 99% 성장한 수치입니다. 회사의 2024년 전체 연간 순수익은 $36.2-36.5 백만에 이를 것으로 예상되며, 이는 2023년의 $13.6 백만 대비 167% 증가한 것입니다.
2024년 4분기의 주요 사항으로는 약 13,300 FUROSCIX 용량이 배송되어 3분기 10,800 용량에 비해 23% 증가했습니다. 총매출-순매출 할인율은 18-19%로 예상되며, 2024년 3분기의 15.7%와 비교됩니다. 회사는 2024년을 약 $75.7 백만의 현금 및 현금성 자산으로 종료하였으며, 매출채권은 2024년 9월 대비 27% 증가했습니다.
SCPH는 전문 약국을 추가하여 유통 네트워크를 확장하였으며, 2025년에는 Medicare 개혁 시행 및 만성 신장 질환 환자를 위한 FUROSCIX 적응증 확대 가능성을 통해 성장이 있을 것으로 예상하고 있습니다.
scPharmaceuticals (SCPH) a rapporté de solides résultats préliminaires pour le quatrième trimestre de 2024, avec un chiffre d'affaires net attendu entre $12-12.3 millions, représentant une croissance de 99 % par rapport au quatrième trimestre 2023. Les revenus nets annuels de l'entreprise pour 2024 devraient atteindre $36.2-36.5 millions, soit une augmentation de 167 % par rapport aux 13,6 millions de dollars de 2023.
Les points forts du quatrième trimestre 2024 incluent environ 13 300 doses de FUROSCIX expédiées, soit une augmentation de 23 % par rapport aux 10 800 doses du troisième trimestre. Le rabais brut-net devrait être de 18-19 %, contre 15,7 % au troisième trimestre 2024. La société a terminé 2024 avec environ $75.7 millions en liquidités et équivalents, avec des comptes clients en augmentation de 27 % par rapport à septembre 2024.
SCPH a élargi son réseau de distribution en ajoutant une pharmacie spécialisée et prévoit une croissance en 2025 grâce à l'implémentation de la réforme de Medicare et à une possible expansion de l'indication de FUROSCIX pour les patients atteints de maladies rénales chroniques en mars.
scPharmaceuticals (SCPH) hat starke vorläufige Ergebnisse für das vierte Quartal 2024 berichtet, mit einem erwarteten Nettoumsatz zwischen $12-12.3 Millionen, was einem Wachstum von 99% im Vergleich zum vierten Quartal 2023 entspricht. Der Nettoumsatz des Unternehmens für das gesamte Jahr 2024 wird voraussichtlich $36.2-36.5 Millionen erreichen, was einem Anstieg von 167% gegenüber den $13.6 Millionen im Jahr 2023 entspricht.
Die Highlights des vierten Quartals 2024 umfassen etwa 13.300 FUROSCIX-Dosen, die versandt wurden, was einem Anstieg von 23% im Vergleich zu den 10.800 Dosen im dritten Quartal entspricht. Der Brutto-zu-Netto-Rabatt wird voraussichtlich bei 18-19% liegen, im Vergleich zu 15,7% im dritten Quartal 2024. Das Unternehmen schloss das Jahr 2024 mit etwa $75.7 Millionen an Bargeld und Barmitteln ab, während die Forderungen um 27% seit September 2024 gestiegen sind.
SCPH hat sein Vertriebsnetz durch die Hinzufügung einer Fachapotheke erweitert und rechnet mit einem Wachstum im Jahr 2025 durch die Umsetzung der Medicare-Reform und einer möglichen Ausweitung der FUROSCIX-Indikation für Patienten mit chronischen Nierenerkrankungen im März.
- Q4 2024 revenue expected at $12-12.3M, up 99% YoY
- Full-year 2024 revenue projected at $36.2-36.5M, up 167% YoY
- Q4 FUROSCIX shipments increased 23% QoQ to 13,300 doses
- Strong cash position of $75.7M as of December 31, 2024
- 27% increase in accounts receivable from Q3 2024
- Gross-to-net discount increased to 18-19% in Q4 from 15.7% in Q3 2024
Insights
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately
Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of
Preliminary unaudited full year 2024 net revenue expected to be approximately
BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced preliminary results for the fourth quarter and full year 2024, including fourth quarter 2024 net FUROSCIX revenue and unaudited cash and cash equivalents.
“We continue to see FUROSCIX net revenue growth driven by our ongoing expansion efforts, including collaborations w ith top Integrated Delivery Networks and hospital systems, and the initial impact of our expanded field sales force,” stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals. “As we enter 2025, we look forward to the first full quarter with our expanded sales force and anticipated further growth in Class IV heart failure patients. We anticipate additional growth with the implementation of the Medicare redesign and our upcoming PDUFA date in March to expand the FUROSCIX indication to include chronic kidney disease patients. We expect a mid-year submission of the sNDA for our Autoinjector product candidate which should accelerate future growth.”
Corporate Updates and Preliminary Unaudited Q4 and FY 2024 Financial Results:
- scPharmaceuticals expects preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of
$12 million to$12.3 million , representing a22% increase from the third quarter of 2024 at the mid-point of the range - The gross-to-net discount is expected to be in the range of
18% to19% , compared to the gross-to-net discount of15.7% in the third quarter of 2024 - Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of
$36.2 million to$36.5 million , representing167% growth over the full year 2023 at the mid-point of the range - Approximately 13,300 FUROSCIX doses shipped in the fourth quarter, representing an approximately
23% increase from the 10,800 doses shipped in the third quarter of 2024 - Added a specialty pharmacy to improve coverage of expanded geography
- Unaudited cash, and cash equivalents were approximately
$75.7 million as of December 31, 2024, which does not include an approximate increase in accounts receivable of27% over the balance as of September 30, 2024
These preliminary select financial results are unaudited and subject to change. scPharmaceuticals will report its final and complete fourth quarter and full-year 2024 financial results in March 2025. The Company has not completed its financial closing procedures for the quarter or year ended December 31, 2024, and its actual results could be materially different from these preliminary financial results.
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our anticipated financial results of the fiscal quarter and full year ended December 31, 2024; our commercial strategy for FUROSCIX and anticipated sales; the impact of our ongoing expansion efforts including our expanded sales force; anticipated additional growth with the implementation of the Medicare redesign; the PDUFA target action date related to the NDA seeking to expand the FUROSCIX indication to include the treatment of fluid overload in CKD; the potential submission of the sNDA for the Autoinjector; and the timing of any of the foregoing. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other product candidates; risks related to the receipt of regulatory approval for our product candidates; risks related to our ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any of our product candidates, if approved; risks related to our history of operating losses, we have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may never achieve or maintain profitability; we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts; the terms of our credit facility place restrictions on our operating and financial flexibility, and we may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due; clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and any difficulties or delays in the commencement or completion, or the termination or the potential for the results from any clinical trials to support submission of sNDAs or comparable regulatory applications; and the risk that global economic factors and uncertainties will impact the Company’s operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
Nick@GilmartinIR.com
FAQ
What was SCPH's expected revenue growth in Q4 2024 compared to Q4 2023?
How many FUROSCIX doses did SCPH ship in Q4 2024?
What is SCPH's cash position as of December 31, 2024?
What was SCPH's projected full-year revenue for 2024?
How did SCPH's gross-to-net discount change in Q4 2024?
